Replies to post #126556 on Arrayit Corporation (ARYC)

[Spike1976]

you know the answers to them questions. You are just making this look better.

[PennyStock Alert]

Have someone read the last several ARYC Press Releases to you and you’ll know why

[BBstocks77]

Press Releases and important TWEETS:

1-3-18 Arrayit advanced microarray technology to be incorporated into a clinical trial by a major pharmaceutical giant in a development that could significantly increase revenues and earnings in 2018 http://arrayit.com/Products/products.html …

5-19-18: Sunnyvale, May 09, 2018 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces receipt of a new clinical licensure from the Centers for Medicare and Medicaid Services (CMS), which oversees the Clinical Laboratory Improvement Amendments (CLIA) Program. Arrayit's new CLIA license, issued in conjunction with the Department of Health and Human Services (HHS) and the California Department of Public Health (CDPH), provides certification for its Silicon Valley clinical laboratory.
https://www.marketwatch.com/story/arrayit-corporation-announces-new-clinical-licensure-from-the-centers-for-medicare-and-medicaid-services-2018-05-09?siteid=bigcharts&dist=bigcharts

5-21-18: Arrayit Corporation Scores 100% on Proficiency Testing Conducted by the College of American Pathologists as clinical team aces CAP PT in highly quantitative measurements of IgE using a blinded study protocol. Congratulations to our amazing clinical team!
http://www.globenewswire.com/news-release/2018/05/16/1507332/0/en/Arrayit-Corporation-Scores-100-on-Proficiency-Testing-Conducted-by-the-College-of-American-Pathologists.html

5-30-18: Sunnyvale, CA , May 30, 2018 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces that the company has achieved the clinical testing accuracy required for reimbursement under Medicare and Medicaid. Accuracy testing, supervised by the College of American Pathologists (CAP), assesses quantitative measurements of the immunoglobulin E (IgE) regulated analyte in the general immunology proficiency testing program. Arrayit’s testing performance included a score of 100% on the SA-2018 proficiency event and constituted successful cumulative performance required by the Centers for Medicare and Medicaid Services (CMS) over a one-year testing period. CMS regulates approximately 260,000 clinical laboratories through the Clinical Laboratory Improvement Amendments (CLIA) program, and proper certification is required to receive Medicare and Medicaid payments.
https://www.marketwatch.com/story/arrayit-corporation-achieves-testing-accuracy-required-for-medicare-and-medicaid-reimbursement-2018-05-30?siteid=bigcharts&dist=bigcharts

6-18-18: June 18, 2018 - Sunnyvale, CA - Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces that the company has engaged a nationwide network of professional sales representatives ("sales reps") to sell and distribute the company's allergy tests across the Continental United States, with focus areas in the Pacific Northwest, West, Southwest, Rocky Mountain, Midwest, Northeast and Southeast regions. The network comprises 1,700 sales professionals including 500 sales reps with specific training in finger stick sampling, blood card collection and microarray technology. This extensive professional network will be used to enroll hospitals, health maintenance organizations (HMOs), doctor's and dentist's offices, health clinics and retail stores into the allergy-testing program.
https://www.marketwatch.com/story/arrayit-corporation-announces-nationwide-allergy-testing-sales-and-distribution-network-2018-06-18?siteid=bigcharts&dist=bigcharts

6-29-18: Arrayit signs capital financing agreement with a top buy-side analyst at a leading corporate intelligence firm headquartered in London UK with offices in New York and providing buy-side intelligence to high net worth retail investors, institutional investors and hedge funds.
https://twitter.com/arrayit/status/1012723616373280768

7-2-18: Sunnyvale, July 02, 2018 (GLOBE NEWSWIRE) -- July 2, 2018 - Sunnyvale, CA – Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces that the company has completed an allergy testing pilot program for one of nation’s largest chains of retail stores. The retailer collected finger stick blood specimens from 126 customers at their in-store clinics, and shipped the blood cards to Arrayit for processing. Arrayit processed the specimens and reported 126 quantitative total immunoglobulin E (IgE) measurements and 15,120 allergen-specific determinations indicative of food and environmental allergies. The test results were reviewed and approved by the retail chain’s Chief Medical Officer.
https://www.marketwatch.com/story/arrayit-corporation-completes-allergy-testing-pilot-program-for-one-of-the-nations-largest-retail-chains-2018-07-02?siteid=bigcharts&dist=bigcharts

7-3-18: Arrayit senior management receives NASDAQ and NYSE up-listing proposal from small and mid-cap consulting experts http://uplisting.com focusing on growth companies seeking to improve and enhance shareholder value by listing on a major stock exchange http://www.uplisting.com
https://twitter.com/arrayit/status/1014187818891935744
7-3-18: Arrayit provides 7/2/18 FDA update: (1) excellent meeting, (2) large attendance by FDA top brass, (3) insightful and instructive, (4) our entire clinical team wishes to thank the agency for their feedback and generosity, and (5) we believe that our test will receive FDA approval.
https://twitter.com/arrayit/status/1014171600051007488
7-8-18: Arrayit web design team updates investor main page and 33 sub-pages including updated information and links regarding Arrayit technology, auditors, biochemistry 101, celebrity spokesperson, CEO, SEC filings, XBRL filings and many other ARYC investor topics http://arrayit.com/Microarray_Investor/microarray_investor.html …
https://twitter.com/arrayit/status/1016023938470576128
7-16-18: July 16, 2018 - Sunnyvale, CA - Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces the sale of clinical instrumentation to the United States Food and Drug Administration (FDA). Arrayit uses the same clinical instrumentation in its Clinical Laboratory Improvement Amendments (CLIA) laboratory licensed by the Centers for Medicare and Medicaid Services (CMS) and the State of California Department of Public Health (CDPH). The instrumentation reads and reports test results for the company's allergy and dietary wellness tests and pipeline tests for ovarian cancer and Parkinson's Disease (PD).
https://www.marketwatch.com/press-release/arrayit-corporation-reports-clinical-instrumentation-sale-to-the-united-states-food-and-drug-administration-2018-07-16?siteid=bigcharts&dist=bigcharts

7-25-18: Arrayit senior management completes analyst call with top buy side analyst at the prestigious Alpha Deal Group headquartered in New York NY USA and providing premium independent due diligence for high net-worth retail, instituional and hedge fund customers (link: http://www.alphadealgroup.com) alphadealgroup.com
https://twitter.com/arrayit/status/1022158461302267905

7-30-18: Sunnyvale, July 30, 2018 (GLOBE NEWSWIRE) -- July 30, 2018 - Sunnyvale, CA – Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, signs allergy testing contracts with a consortium of medical clinics nationwide. The network comprises 178 medical clinics in 29 of the 48 contiguous United States including the Northeast, Southeast, Midwest, South, Southwest, Pacific and Pacific Northwest regions, with single clinics staffing up to 70 physicians. The clinics are using Arrayit allergy testing services to assist physicians in diagnosing and treating allergy and asthma across a wide range of medical specialties and focus areas including anti-aging, back pain and sciatica, chiropractic care, dermatology, digestive health, ear nose and throat (ENT), family medicine, gastroenterology, health and beauty, immunology, integrative medicine, internal medicine, obesity, obstetrics and gynecology (OB-GYN), pain relief, pediatrics, personalized medicine, preventative medicine, primary care, rehabilitation, sinus, spinal care, urgent care, weight loss, wellness and women’s health.
Arrayit recently established a nationwide sales network of 1,700 sales professionals to sell and distribute the company’s finger stick microarray tests to medical clinics and retail chains, completed allergy pilot testing with one the nation’s largest chains of retail stores, met with top officials at the United States Food and Drug Administration (FDA) to discuss FDA approval of a major product line, and reported the sale of clinical instrumentation to the FDA. Arrayit microarray tests conveniently use a few drops of patient blood collected on a blood card to assist doctors in identifying and treating food intolerance, allergy and asthma, and pipeline indications for more serious conditions such as ovarian cancer and Parkinson’s Disease. Doctors can use allergy test results as quantitative tools to inform decisions regarding allergy medicines, immunotherapy, food elimination and lifestyle changes.
https://www.marketwatch.com/press-release/arrayit-corporation-signs-allergy-testing-contracts-with-a-nationwide-consortium-of-medical-clinics-2018-07-30?siteid=bigcharts&dist=bigcharts

8-7-18: Arrayit senior management submits $5,000,000 strategic investment proposal to a companion diagnostics and therapeutics leader headquartered in the San Francisco Bay Area USA and commercializing medicines for the massive $45 billion neurodegenerative market
https://twitter.com/arrayit/status/1026860386782339072

8-13-18: August 13, 2018 - Sunnyvale, CA - Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, has been approved for in-store allergy testing promotions by a major United States retailer. Arrayit sales and marketing experts will conduct allergy test promotions in-store, and medical professionals at in-store clinics will collect finger stick blood specimens. Two thousand retail locations nationwide averaging 3,000 customer visits per store per day would give Arrayit access to 6 million retail customers daily, creating the potential for exponential sales growth. This promotional campaign required rigorous vetting and high-level corporate approval by the retailer, which reports revenues exceeding $50 billion annually.

https://www.marketwatch.com/press-release/arrayit-corporation-receives-approval-for-in-store-promotions-by-a-major-retail-chain-2018-08-13?siteid=bigcharts&dist=bigcharts

8-27-18: August 27, 2018 - Sunnyvale, CA - Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces allergy testing partnerships with multiple providers of allergen immunotherapy products including sub-cutaneous, sublingual, and oral allergy medicines designed to treat patients of allergy and asthma. Allergen immunotherapy, a time-tested clinical approach, can reduce or eliminate allergy and asthma symptoms by lowering the levels of specific cellular proteins known as immunoglobulin E (IgE) molecules that activate the immune system and trigger immune responses. Through these partnerships, doctors prescribing Arrayit allergy tests gain access to a portfolio of safe, effective and convenient allergy medicines for their allergy and asthma patients, including custom immunotherapy products formulated upon review of quantitative allergy test results.
https://www.marketwatch.com/press-release/arrayit-corporation-announces-allergy-testing-partnerships-with-major-allergy-therapeutics-providers-2018-08-27-51843016?siteid=bigcharts&dist=bigcharts

9-10-18: September 10, 2018 - Sunnyvale, CA - Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces that Arrayit's proprietary finger stick allergy microarray test has been approved for direct Medicare billing by the Centers for Medicare and Medicaid Services (CMS). The Medicare national health insurance program provides health insurance to more than 55 million Americans annually, including 46 million seniors and 9 million younger people. CMS projects a 2018 Medicare budget of approximately $705,000,000,000 ($705 billion dollars), representing about 17% of total federal spending.
https://www.marketwatch.com/press-release/arrayit-corporation-approved-for-direct-medicare-billing-by-the-centers-for-medicare-and-medicaid-services-2018-09-10?siteid=bigcharts&dist=bigcharts

9-24-18: Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, reports the shipment of clinical instrumentation and quantification software to the United States Food and Drug Administration (FDA). Arrayit uses the same instrumentation and software to test for allergy and food intolerance as well as pipeline indications for ovarian cancer and Parkinson's Disease (PD). Testing is performed in the company's Clinical Laboratory Improvement Amendments (CLIA) laboratory licensed by the California Department of Public Health (CDPH) and the Center for Medicare and Medicaid Services (CMS).
https://www.marketwatch.com/press-release/arrayit-corporation-ships-clinical-instrumentation-and-software-to-the-united-states-food-and-drug-administration-2018-09-24?siteid=bigcharts&dist=bigcharts

10-8-18: Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, reports that its clinical team aced three consecutive rounds of blinded-specimen Proficiency Testing (PT) with the College of American Pathologists (CAP). The SC-2017, SA-2018 and SB-2018 triannual CAP Diagnostic Immunology Surveys require highly quantitative measurements of immunoglobulin E (IgE), the antibody molecules measured by the company's finger stick allergy microarray tests. Arrayit's highly accurate PT performance showcases the robustness of the company's proprietary allergy testing platform and reagents, which are increasingly being leveraged by doctors as a tool to diagnose and treat allergy and asthma.
https://www.marketwatch.com/press-release/arrayit-corporation-aces-three-consecutive-rounds-of-proficiency-testing-with-the-college-of-american-pathologists-2018-10-08?siteid=bigcharts&dist=bigcharts

10-22-18: Published: Oct 22, 2018 5:30 a.m. ET
Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, launches a fully automated allergy testing portal for doctors and clinics to streamline and accelerate the allergy testing and treatment process. The Patient Data Solutions (PDS) allergy-testing suite is secure and fully compliant with Health Insurance Portability and Accountability Act (HIPAA) requirements to ensure the privacy of patient health records. The new PDS portal allows doctors to order allergy blood card collection kits, request express mail shipping labels, download allergy test results, and order immunotherapy products from our independent allergy therapeutics partners. The PDS portal, which is free of charge to doctors and clinics, offers continuous, real-time technical assistance to ensure a positive on-line experience.
https://www.marketwatch.com/press-release/arrayit-corporation-launches-patient-data-solutions-allergy-testing-portal-for-doctors-and-clinics-2018-10-22?siteid=bigcharts&dist=bigcharts

10-31-18: Arrayit provides an update to shareholders. We are currently is a quiet period regarding our financials. Our next financial announcement will be the filing of our 10-K and 10-Q forms through 2018. Thanks everyone for your continued support and patience! http://arrayit.com/index.html
https://twitter.com/arrayit/status/1057654833040113665

11-5-18: Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces expansion of its proprietary finger stick microarray allergy testing platform to a growing number of major market brands. Highly automated Arrayit technology is inherently suited to leveraging multiple brands and their unique venues and relationships to reach a larger number of allergy patients more quickly. Each brand serving major retail chains, large government agencies, medical clinics and doctor offices receive the same high-level testing support and treatment options through the company's Patient Data Solutions (PDS) on-line allergy testing portal and therapeutics affiliates.

11-12-18: Arrayit manufacturing team expands weekend production and completes a $5.75 million manufacturing run for a top client commercializing finger stick microarray tests for consumer lifestyle and wellness testing in the massive $3.3 trillion healthcare markets http://arrayit.com/Clinical/clinical.html …
https://twitter.com/arrayit/status/1062017703165087744

11-19-18: Sunnyvale, Nov 19, 2018 (GLOBE NEWSWIRE via COMTEX) -- Sunnyvale, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces an allergy testing agreement with Northern California healthcare leader Sutter Health. The company is providing its proprietary microarray-based finger stick allergy testing services to Sutter Health via doctors in the Sutter Health-affiliated Palo Alto Medical Foundation. Sutter Health, one of the nation's largest healthcare networks, is headquartered in Sacramento California and has 50,000 employees including 12,000 physicians and 14,000 nurses serving 3 million Northern California patients. Sutter Health draws 19% of its revenue from the California Medical Assistance Program (Medi-Cal) and reports total patient service revenues of $12,000,000,000 ($12 billion) annually.
https://www.marketwatch.com/press-release/arrayit-corporation-announces-allergy-testing-agreement-with-sutter-health-2018-11-19?siteid=bigcharts&dist=bigcharts

12-3-18: Sunnyvale, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces a new allergy testing services agreement with a major healthcare company specializing in patient health and wellness. Arrayit offers simple non-invasive testing services that measure reactivity of immunoglobulin E (IgE) antibodies to an extensive panel of food, environmental and specialty allergens as a precision healthcare solution to assist physicians in the diagnosis and treatment of allergy and asthma. The healthcare leader provides health and pharmacy services to more than 10 million retail, commercial and corporate customers and reports revenues exceeding $35,000,000,000 ($35 billion dollars) annually.
https://www.marketwatch.com/press-release/arrayit-corporation-announces-allergy-testing-services-agreement-with-a-major-health-and-wellness-provider-2018-12-03?siteid=bigcharts&dist=bigcharts

12-3-18: Arrayit production team completes $4.1 million microarray manufacturing run to expand inventory for major clinical healthcare accounts using our doctor-prescribed proprietary finger stick microarray tests to improve dietary and allergy health and wellness http://arrayit.com/Clinical/clinical.html …
https://twitter.com/arrayit/status/1069649633645813765

12-4-18: Arrayit production team expands manufacturing adding an additional overnight production run to complete a $5.0 million manufacturing run to build inventory for top accounts using our finger stick microarray allergy testing services for health and wellness http://arrayit.com/Clinical/clinical.html …
https://twitter.com/arrayit/status/1069992914669907969

12-17-18: Sunnyvale, Dec 17, 2018 (GLOBE NEWSWIRE via COMTEX) -- Sunnyvale, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, reports fulfillment of a clinical instrumentation contract with the United States Food and Drug Administration (FDA), which involves an exacting series of contractual steps including receiving the solicitation, placing the bid, winning the award, receiving the purchase order, shipping the system, gaining an installation and acceptance notice, and reporting FDA approval of payment for fulfillment of the contract. The clinical instrumentation in the FDA contract is the same technology deployed by Arrayit in its Clinical Laboratory Improvement Amendments (CLIA) laboratory licensed by the Centers for Medicare and Medicaid Services (CMS) and the State of California Department of Public Health (CDPH) for allergy and dietary wellness testing and pipeline tests for ovarian cancer and Parkinson's Disease (PD).
https://www.marketwatch.com/press-release/arrayit-corporation-fulfills-clinical-instrumentation-contract-with-the-united-states-food-and-drug-administration-2018-12-17-51843025?siteid=bigcharts&dist=bigcharts
12-26-18: Arrayit business development team completes conference call with a leading healthcare focused venture capital firm headquartered in New York NY USA and seeking partnering opportunities in the lucrative high-growth US health and wellness testing markets http://arrayit.com/Clinical/clinical.html …
https://twitter.com/arrayit/status/1077980929417654272
12-31-18: Dec 31, 2018 (GLOBE NEWSWIRE via COMTEX) -- Sunnyvale, Dec. 31, 2018 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces a letter to shareholders from Arrayit Chief Executive Officer Rene Schena. The letter is downloadable at this link:
http://www.arrayit.com/confidential/Letter-to-Arrayit-Shareholders.pdf
At year end, we implemented a new electronic medical billing solution and we expect to bill $1 million per week for our health and wellness tests. The actual contribution of medical reimbursement to our revenues and earnings will be detailed in financial reports, which we anticipate filing in the coming quarter.
1-10-18: Arrayit financial team completes 2018 inventory observation site visit this week at our Silicon Valley California USA headquarters with Prime Global independent auditing firm Rosenberg Rich Baker Berman & Company RRBB headquartered Somerset New Jersey USA http://www.rrbb.com
1-14-19: Sunnyvale, Jan 14, 2019 (GLOBE NEWSWIRE via COMTEX) -- Sunnyvale, Jan. 14, 2019 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, reports that its clinical team has aced four consecutive rounds of proficiency testing (PT) with a nationally recognized proficiency testing leader. Proficiency testing requires precise quantification of specific cellular immunoglobulin E (IgE) antibodies, the protein biomarkers often associated with allergy and asthma. PT samples are blind-tested for IgE concentration as a means of evaluating the accuracy of a clinical test. Arrayit's clinical team aced four consecutive rounds of PT over a 12-month period, indicating that its microarray testing technology is highly accurate when assessed by an independent third party.
https://www.marketwatch.com/press-release/arrayit-corporation-aces-fourth-consecutive-round-of-proficiency-testing-with-a-top-proficiency-testing-company-2019-01-14-5184301?siteid=bigcharts&dist=bigcharts
1-28-19: Sunnyvale, Jan 28, 2019 (GLOBE NEWSWIRE via COMTEX) -- Sunnyvale, Jan. 28, 2019 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, reports that its proprietary microarray-based finger stick allergy testing services are endorsed by prestigious health and wellness leader First Pediatrics Medical Group. Headquartered in Fresno, California USA
https://www.marketwatch.com/press-release/arrayit-corporation-allergy-testing-services-endorsed-by-leading-pediatrics-medical-group-2019-01-28?siteid=bigcharts&dist=bigcharts
2-6-19: Arrayit production team commences $96,000 microarray manufacturing run to build inventory for a top account HQ in the United States and commercializing proprietary finger stick microarray tests for the lucrative high-growth health and wellness markets http://arrayit.com/Clinical/clinical.html …
2-11-19: Sunnyvale, Feb 11, 2019 (GLOBE NEWSWIRE via COMTEX) -- Sunnyvale, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, reports that its nationwide allergy testing consortium has more than doubled in the past six months to 410 medical clinics. The rapidly expanding network using the company's powerful finger stick allergy testing services comprises…
https://www.marketwatch.com/press-release/arrayit-corporation-nationwide-allergy-testing-network-doubles-to-more-than-400-healthcare-clinics-2019-02-11-51842952?siteid=bigcharts&dist=bigcharts
2-25-19: Sunnyvale, Feb 25, 2019 (GLOBE NEWSWIRE via COMTEX) -- Sunnyvale, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces that its physician-prescribed finger stick allergy testing services are now available in-network from a leading commercial health insurance company.
https://www.marketwatch.com/press-release/arrayit-corporation-announces-in-network-allergy-testing-services-contract-with-a-top-five-commercial-healthcare-benefits-company-2019-02-25-6184153?siteid=bigcharts&dist=bigcharts
3-11-19: Sunnyvale, March 11, 2019 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, increases weekly guidance for medical billing associated with its physician-prescribed allergy testing services from $1,000,000 ($1 million) per week as presented in the December 31 2018 CEO Letter to Shareholders, to $2,000,000 ($2 million) per week effective immediately. The 100% weekly guidance increase from $1 million to $2 million per week for fiscal year 2019 (FY2019) is based on medical billing growth during the first quarter of FY2019, the number of new clinics being added to our Patient Data Solutions portal, and the rate of allergy testing services adoption in the marketplace.
3-19-19: Arrayit senior management receives senior exchange listing information from up-listing experts http://Uplisting.com headquartered in New York NY USA and facilitating NASDAQ listings by maximizing public company business goals and shareholder value http://www.uplisting.com
https://twitter.com/arrayit/status/1108083028260052992




Dear , We appreciate your ongoing support and participation. Please see these links for an update on the very exciting Life Marker Chip ExoMars mission. Thanks, Mark

https://www.sciencedirect.com/science/article/pii/S0032063312001006

https://en.wikipedia.org/wiki/ExoMars

https://www.nasdaq.com/press-release/arrayit-corporation-increases-weekly-guidance-for-doctorprescribed-allergy-testing-clinical-services-20190311-00106

http://www.arrayit.com/confidential/Letter-to-Arrayit-Shareholders.pdf

[kex0414]

Fidelity is not for OTC or Pinks.

[StockDetective]

Is that your $65,000 + bid @ .1430 that’s currently hidden?

[mfdesigner]

Too busy counting money to answer your questions. The world is full of mysteries isn't it? Life is to short to know the answers to all. Enjoy the rise while you can.